The 1‐year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan. Issue 4 (24th May 2021)

• Record Type: Journal Article
• Authors: Mukai, Shigeto; Nomi, Masashi; Yamada, Shogo; Yanagiuchi, Akihiro; Sengoku, Atsushi
• Is Part Of: LUTS. Volume 13:Issue 4(2021)
• Page Start: 448
• Page End: 455
• Publication Date: 2021-05-24
• Subjects: continuity of administration -- mirabegron -- overactive bladder -- vibegron; Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12391
• Languages: English
• ISSNs: 1757-5664

Abstract

Abstract: Objectives: To compare the 1‐year continuation rate and discontinuation factors between vibegron and mirabegron in patients with neurogenic and nonneurogenic overactive bladder. Methods: Continuation or discontinuation of the target drugs and reasons for discontinuation as well as patients' grounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to the inclusion and exclusion criteria, 180 cases taking mirabegron and 132 taking vibegron were adjusted for intergroup variability by propensity score matching. We performed Cox proportional hazards regression for the 1‐year continuation rate and Fine‐Gray proportional hazards regression for the 1‐year cumulative incidence of discontinuation events. Subgroup analysis was also performed for the background factors related to the 1‐year continuation rate. Results: The 1‐year continuation rate was 83.8% for vibegron and 58.2% for mirabegron, and the hazard ratio was 0.32 (95% CI: 0.18‐0.57, P < .001) as for an incidence of discontinuation events of vibegron against mirabegron. The incidence of discontinuation due to an inadequate efficacy was 8.7% for vibegron and 29.1% for mirabegron, and similarly the hazard ratio was 0.26 (95% CI: 0.12‐0.55, P < .001). The subgroup analysis indicated a similar tendency in each subgroup except for that of catheterization, and there was no significant interaction between the groups. Conclusions: It is suggested that vibegron is superior to mirabegron in the continuity of administration in neurogenic and nonneurogenic overactive bladder populations without catheterization with fewer discontinuations due to inadequate efficacy.